On Wednesday, BeOne Medicines ADR earned a positive adjustment to its Relative Strength (RS) Rating, from 89 to 92.
How To Use Stock Charts To Stay Profitable And Protected
This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks matches up against all other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an RS Rating of over 80 in the early stages of their moves.
The IBD 50 stock has risen more than 5% past a 287.88 entry in a second-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Earnings growth increased in the company's most recent report from 0% to 923%, but revenue fell from 49% to 42%.
BeOne Medicines ADR earns the No. 6 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
